Results from a 78-week single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with moderate to severe long-chain fatty acid oxidation disorders (LC-FAOD)

Authors
Category Primary study
JournalMolecular Genetics and Metabolism
Year 2018
This article has no abstract
Epistemonikos ID: 702b26a6610ac473313a7983f0d61b24d07f87fb
First added on: Feb 09, 2025